Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Kidney disease and Women's heart risk: hormones may hold the key

NCT ID NCT05471518

Knowledge-focused Sponsor: University of Colorado, Denver Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study looked at how sex hormones, especially estradiol, affect blood vessel function in women with chronic kidney disease (CKD). Researchers compared pre- and post-menopausal women with CKD to healthy women of the same age. They measured blood vessel dilation and stiffness, along with hormone levels, to understand why women with CKD face higher heart disease risk. The goal is to uncover whether hormone changes from CKD contribute to blood vessel damage.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this research could help explain why women with CKD have higher heart disease risk and point toward hormone-based treatments to protect their blood vessels.
What could go wrong
This is a small, completed observational study (51 participants) that only measures associations, not causes. The findings may not apply to all women with CKD or lead directly to treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

51 people

The number who actually took part.

Started

Jul 2021

Finished

Nov 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Pre- and post-menopausal women with CKD vs. age-matched healthy women

Ages

18 to 75 years

Sex

Female participants only

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Pre- (18-44 y) and post-menopausal (55-75 y) women 2. Individuals with CKD including stage 3-4 (eGFR 15-59 ml/min/1.73m2) determined by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation AND/OR urinary albumin-creatinine ratio (UACR) ≥ 30. 3. Controls must be healthy (free from hypertension, kidney disease, cardiovascular disease, diabetes, and other chronic disease as assessed by self-report, medical history, and screening labs). Premenopausal healthy women must have a regular menstrual cycle (25-35 d). Exclusion Criteria: 1. Perimenopausal (45-54 y) women 2. Pregnancy, lactation, or less than one year post-partum 3. Use of hormonal birth control methods, hormone replacement therapy, or a levonorgestrel intrauterine device (IUD) insertion for a duration less than 6 months 4. Advanced CKD requiring dialysis 5. History of kidney transplant 6. Use of immunosuppressant medications (unless taking a stable dosage for a quiescent disease in CKD group) 7. Antioxidant and/or omega-3 fatty acid use within the 2 weeks prior to testing 8. Current tobacco or nicotine use or history of use in the last 12 months 9. Marijuana use within 2 weeks prior to testing 10. Uncontrolled hypertension in CKD group (BP \>140/90 mmHg) 11. Atrial fibrillation 12. Active infection or antibiotic therapy 13. Hospitalization in the last month

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic kidney diseases are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic kidney disease chronic renal failure syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic kidney diseases

Contacts and locations

Locations

  • University of Colorado Anschutz Medical Campus

    Aurora, Colorado, 80045, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.